MarketPulse

Phase 3 clinical trials

10 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Eyepoint, Inc.

EyePoint Faces Revenue Collapse as DURAVYU AMD Trials Advance Into 2026

EyePoint reports 97% revenue decline to $0.7M in Q1 2026 amid $84.8M net loss, but maintains $223M cash runway through Q4 2027 as DURAVYU Phase 3 trials advance.
EYPTregulatory approvalretinal diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley CEO to Present at Needham Conferences as Psychedelic Drug Advances

AtaiBeckley will showcase its FDA-designated breakthrough therapy BPL-003 at Needham conferences in April, advancing toward Phase 3 trials in 2026.
ATAItreatment-resistant depressionFDA Breakthrough Therapy Designation
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Viking Therapeutics' Billion-Dollar Bet: Can VK2735 Compete in the Weight-Loss Gold Rush?

Viking Therapeutics' VK2735 targets the $100+ billion weight-loss market. Success could drive massive stock appreciation, but clinical and competitive risks remain substantial.
LLYVKTXbiotechregulatory approval
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Clinical Trials, Alleged Investor Deception

Mereo BioPharma faces class action lawsuit alleging false statements about failed Phase 3 trials ORBIT and COSMIC. Investors from June 2023-December 2025 eligible; lead plaintiff deadline April 2026.
MREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Xenon Pharma Raises $650M in Upsized Offering to Fund Pipeline Growth

Xenon Pharmaceuticals prices $650M upsized offering at $57/share with 10.5M shares. Proceeds fund pipeline acceleration; closes March 2026.
XENEpublic offeringcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Mereo BioPharma Faces Class Action Over Failed Drug Trials; Stock Crashes 87.7%

Robbins LLP sues Mereo BioPharma over setrusumab trial failures; stock crashes 87.7% to $0.29 after December 29 announcement.
MREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

EyePoint Sets March 4 Earnings Call as Pipeline Advances Toward Key Milestones

EyePoint will report 2025 results March 4, highlighting pipeline progress. Lead drug DURAVYU™ advances toward Phase 3 trials for retinal diseases with key data expected mid-2026.
EYPTbiopharmaceuticalretinal diseases
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Viking Therapeutics Advances Weight-Loss Candidate Into Late-Stage Trials

Viking Therapeutics advances obesity drug VK2735 into Phase 3 trials after positive interim results, positioning itself in the competitive weight-loss pharmaceutical market.
LLYNVOVKTXbiotechweight loss drugs
GlobeNewswire Inc.GlobeNewswire Inc.··Abivax Sa

Abivax Demonstrates Anti-Fibrotic Potential of Obefazimod at ECCO 2026

Abivax presented evidence that obefazimod shows anti-fibrotic potential in IBD treatment with good safety profile. Phase 3 results expected mid-2026.
ABVXPhase 3 clinical trialsbiomarkers
The Motley FoolThe Motley Fool··Howard Smith

Compass Pathways Surges on Positive Phase 3 Psilocybin Trial Results

Compass Pathways stock surged 44% after positive Phase 3 trial results for psilocybin depression therapy. FDA application expected by end of 2024.
CMPSFDA approvaltreatment-resistant depression